Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

by Qinge Shan, Haiyong Wang, Xiao Han, Jun Guo, Zhehai Wang
Published 2020-10-01

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study

by Qinge Shan, Yanling Fan, Jun Guo, Xiao Han, Haiyong Wang, Zhehai Wang
Published 2019-10-01

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

by Qinge Shan, Jianxiang Shi, Xiaohui Wang, Jun Guo, Xiao Han, Zhehai Wang, Haiyong Wang
Published 2021-05-01

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study

by Qinge Shan, Zhenxiang Li, Jiamao Lin, Jun Guo, Xiao Han, Xinyu Song, Haiyong Wang, Zhehai Wang
Published 2020-01-01

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial...

by Ying Cheng, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Jianxing He, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin, Baolan Li, Jing Zhu
Published 2020-04-01

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-small Cell Lung Cancer

by Xingsheng HU, Shunchang JIAO, Shucai ZHANG, Zhehai WANG, Mengzhao WANG, Cheng HUANG, Rongsheng ZHENG, Kai LI, Jie WANG, Yajie WANG, Xuenong OUYANG, Wenguang LV, Gang CHENG, Chunhong HU, Rongcheng LUO, Yan SUN
Published 2012-10-01

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)

by Caicun ZHOU, Jie WANG, Hong BU, Baocheng WANG, Baohui HAN, You LU, Zhehai WANG, Bo ZHU, Ziping WANG, Qibin SONG, Shengxiang REN, Dongmei LIN, Yayi HE, Xiaohua HU, Hongyun ZHAO, Shukui QIN
Published 2020-02-01

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

by Xiaoyan Si, Li Zhang, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Baohui Han, Kai Li, Qiming Wang, Jianhua Shi, Zhehai Wang, Ying Cheng, Yuankai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin
Published 2019-03-01

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort stud...

by Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu, Pagona Lagiou, Jin Li
Published 2017-09-01

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib...

by Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu, Pagona Lagiou, Jin Li
Published 2018-01-01

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

by Jing Wang, Yizhuo Zhao, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhujun Liu, Baohui Han, Kai Li
Published 2018-12-01

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALT...

by Jianhua Shi, Guimin Chen, Haitao Wang, Xiuxiu Wang, Baohui Han, Kai Li, Qiming Wang, Li Zhang, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Zhian Liu
Published 2021-09-01

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: prom...

by Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang
Published 2019-05-01

A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/Cisplatin and Gemcitabine/Cisplatin as First-line Treatment for Advanced Nonsquamous Non-small Cell Lung C...

by Yan HUANG, Yunpeng LIU, Jianying ZHOU, Nong XU, Baolan LI, Gang WU, Jian FANG, Kai LI, Xiaoqing LIU, Wei LIU, You LU, Mengzhao WANG, Wenchao LIU, Houjie LIANG, Yiping ZHANG, Cheng HUANG, Shunjin WANG, Yajie WANG, Shiying YU, Jianhua CHANG, Zhehai WANG, Zhihuang HU, Li ZHANG
Published 2012-10-01

Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)

by Caicun ZHOU, Jie WANG, Baocheng WANG, Ying CHENG, Zhehai WANG, Baohui HAN, You LU, Gang WU, Li ZHANG, Yong SONG, Bo ZHU, Yi HU, Ziping WANG, Qibin SONG, Shengxiang REN, Yayi HE, Xiaohua HU, Jian ZHANG, Yu YAO, Hongyun ZHAO, Zhijie WANG, Qian CHU, Jianchun DUAN, Jingjing LIU, Shukui QIN
Published 2021-04-01